Abstracts mated to currently suffer from OAB across the five countries. An estimated 2.5 m also have symptoms of urge incontinence. By 2020, 2.1 m additional males are expected to be affected by OAB. The average health care cost associated with managing these patients ranged from €200 in the UK to €732 in Italy. The total cost of OAB in males aged >40 were estimated to be €1.7 billion in 2005: €412 m in Germany; €607 m in Italy; €350 in Spain; €71 m in Sweden and €231 in the UK. By 2020, the total cost of OAB in males is expected to increase to €2 billion. This compares with a total burden of €4.1 billion in 2005 and projected total burden of €5.2 billion in 2020. DISCUSSION: The burden of OAB in males was 40% of the total burden in the overall population aged > 40. The economic burden is likely to increase in line with our prevalence forecasts. Since many males do not seek treatment, the future cost burden may be underestimated. To determine characteristics related to lost productivity in working adults with overactive bladder (OAB) using data from a large US multicenter trial. METHODS: Baseline data were obtained from 2770 participants in the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin (MATRIX). Productivity was assessed using the Work Productivity Questionnaire (WPQ), a modified version of the Work Limitations Questionnaire (WLQ) which captures physical, mental (concentration), time (interruptions and adherence to a schedule), and output (ability to handle workload) domains related to work productivity. Additional questions on demographics, prior OAB treatment, and daily pad use were asked. A WPQ Index was computed to estimate productivity impairment compared to healthy individuals. Characteristics related to productivity loss were determined using group comparisons (t-test). RESULTS: Approximately half (52.7%) of participants were of working age (18-64 years), and 44.9% were employed. The majority were female (92.0%) and white (81.2%). Overall, working participants were approximately 7.9% less productive than healthy individuals. Group comparisons revealed that females experienced greater physical limitations than males (p < 0.05) but had similar time, mental, and output scores. Age younger than 65 was associated with greater impairments of time, mental, and output domains (p < 0.05 for all). Minorities (African Americans, Hispanics, and Asians) experienced significantly less productivity than whites across all categories with the exception that African Americans reported similar time impairments to whites. Productivity scores were inversely related to daily pad use (those using 1-or 2-experiencing higher scores than those using 3 or more), and did not differ between treatment naïve and those previously treated (p > 0.05 for all domains). CONCLUSIONS: OAB causes job interruptions, difficulties in adhering to a schedule, physical limitations, impaired concentration, and reduced ability to handle workload. Females with OAB experience more physical limitations than males, and minorities generally experience greater productivity impairments than whites. ) review was performed on 169,288 discharged patients who received erythropoietin and darbepoetin across 187 hospitals. Based upon an evidence-based medicine framework, utilization of the two drugs was categorized as "on-label" (approved by the FDA), "off-label-supported" (not FDA-approved but with strong evidence supporting off-label use), and "off-label-unsupported" (minimal literature support for off-label indications). A multinomial logistic regression model clustered by hospitals was used. Model covariates were patient demographics, clinical outcomes, physician specialty, hospital size, teaching status, region, drug dose, and number of administrations. RESULTS: Relative to onlabel, physician specialty, patient age group, race, and drug coverage were significant (at the 0.05 level) predictors of off-label use (supported and unsupported). Surgeons were twice as likely to prescribe off-label-unsupported (OFUS) than generalists and four times more likely than specialists. Infants (0-1 years), {RRR-164; 95%CI, 84-319}, children (1-17 years), {RRR-2.30; 95%CI, 1.45-5.0}, and young-adults (18-24 years) {RRR-2.30, 95%CI, 2.07-3.19} were more likely to receive OFUS compared to middle-aged adults (40-59 years), while OFUS prescribing for individuals over 75 years was weakly predictive (RRR-1.28; 95%CI, 1.03-1.6). African-Americans and Native-Americans were twice as likely to receive drugs for off-label-supported (OFS) but half as likely for OFUS use relative to whites. Moreover, Title-V, Worker's compensation, and self-pay patients were more likely to receive OFUS. CONCLUSIONS: Variations in offlabel prescribing among physician specialties may reflect a lack of consensus on practice guidelines. The common use of OFUS prescribing in pediatrics may be explained by the limited clinical trial data on children. Racial differences in OFUS may indicate differing disease prevalence in populations. Knowing causes of off-label prescribing can help decision makers understand the degree to which it is appropriate.
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HP2 PHARMACIST RESPONSE TO COMPUTER-GENERATED DRUG THERAPY ALERTS IN A LONG TERM CARE SETTING
Wegner S 1 , Trygstad T 2 , Christensen DB 2 1 AccessCare, Inc, Morrisville, NC, USA; 2 University of North Carolina, Chapel Hill, NC, USA OBJECTIVES: We implemented a focused drug therapy management intervention aimed at reducing polypharmacy for Medicaid recipients in North Carolina nursing homes. Targeted were patients receiving >18 prescriptions in 90 days. During scheduled monthly home visits, consultant pharmacists providing routine drug regimen reviews also reviewed drug profiles displaying claims-generated drug problem alerts. Pharmacists documented reviews, recommendations and resulting drug therapy changes. Study objectives were to determine: 1) the frequency with which potential drug therapy problems (PDTPs) were found and persisted following interventions, and 2) the impact of interventions on quality, and patient drug costs from a payer perspective. METHODS: Before-after study with comparison group design. Medicaid prescription claims data were compared for three months prior to and following the intervention. RESULTS: In total, 253 nursing homes, 110 consultant pharmacists, and 6344 patients participated in the study arm, with 5160 patients remaining at the end of the follow-up period. At baseline, study group patients used an average of 9.7 prescriptions per month, costing the NC Medicaid program $517(USD). There were 5918 recommendations offered for 3262 patients, or an average of 1.58 per patient. At least one profile-related pharmacist intervention was implemented for 72% of patients, about half involving a switch to a lower cost drug. Two of five alert categories had highly significant reductions in alert persistence of 10.8% and 29.7% respectively versus 0.7% and 14.1% in the comparison group. Drug costs for study group patients were $57 lower than comparison group patients at follow-up (p < 0.05). CONCLUSIONS: A supplemental program of medication reviews for targeted NH patients resulted in a reduction in the persistence of PDTP alerts and was cost beneficial based solely on drug cost savings. This intervention may be a model for future medication therapy management services provided by prescription drug plans under Medicare for patients in long-termcare settings. Survey data to determine the patient and physician factors associated with a prescription for expensive medication and medications with abuse potential side effects in outpatient settings. RESULTS: From 1996 to 2001, about 94.6 million sleepdifficulty related visits were made to outpatient physician offices in the United States. Forty eight percent (45 million) of sleepdifficulty related visits received prescription for medication therapy only. Patients over 65 years of age were 44% less likely (OR: 0.56, 95% CI: 0.35-0.90) to receive an expensive medication prescriptions than patients aged 18-34 years (reference group). Hispanic patients were 56% less likely to receive an expensive medication prescription than Non-Hispanic patients during their visits (OR: 0.44, 95% CI: 0.22-0.88). Male patient visits were 39% less likely than female patient visits to result in receipt of medication with abuse potential among patient visits receiving medication therapy (OR: 0.61, 95% CI: 0.45-0.81). In addition, patients with mental co-morbidities were 80% more likely to be associated with receipt of a prescription of medications with abuse potential than patients with no mental comorbidities (OR: 1.80, 95% CI: 1.31-2.47). CONCLUSIONS: This study indicated that patient's age and ethnicity influence physician prescribing of expensive medications for treatment of sleep difficulties. In addition, increased probability of receipt of medication with abuse potentials in female gender is of concern, when safer alternative medications with lower abuse potentials are easily available.
HP3 PHYSICIAN PRESCRIBING OF SLEEP DISORDER MEDICATIONS IN UNITED STATES OUTPATIENT SETTINGS: FACTORS AFFECTING PRESCRIPTION OF HIGH ABUSE POTENTIAL AND COSTLY MEDICATIONS
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HP4 PRIMARY CARE AND GATEKEEPER MODELS IN GERMANY-WHAT DO THE PATIENTS WANT?
Kielhorn Extensive longitudinal data are required to characterize the outcomes of serious mental disorders. Statistical methods for profiling individual differences in clinical and social outcomes, and the impact of treatment have expanded over the past decade, are now implemented in user friendly software. Our aim was to characterize individual trajectories in patient-rated quality of life scores recorded over two years. METHODS: The sample comprised 10,000 outpatients with schizophrenia participating in the Schizophrenia Outpatient Health Outcomes (SOHO) observational study of health outcomes of antipsychotic treatment which was conducted in 10 European countries. SOHO enrolled schizophrenia outpatients who were initiating or changing their antipsychotic medication. The outcome was
